These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21437444)

  • 1. Recombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients.
    Nascimento B; Lin Y; Callum J; Reis M; Pinto R; Rizoli S
    Clinics (Sao Paulo); 2011; 66(1):101-6. PubMed ID: 21437444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of recombinant factor VIIa in US military casualties for a five-year period.
    Wade CE; Eastridge BJ; Jones JA; West SA; Spinella PC; Perkins JG; Dubick MA; Blackbourne LH; Holcomb JB
    J Trauma; 2010 Aug; 69(2):353-9. PubMed ID: 20699744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant activated coagulation factor VII and bleeding trauma patients.
    Rizoli SB; Nascimento B; Osman F; Netto FS; Kiss A; Callum J; Brenneman FD; Tremblay L; Tien HC
    J Trauma; 2006 Dec; 61(6):1419-25. PubMed ID: 17159685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of protocolized use of recombinant factor VIIa within a massive transfusion protocol in a civilian level I trauma center.
    Morse BC; Dente CJ; Hodgman EI; Shaz BH; Nicholas JM; Wyrzykowski AD; Salomone JP; Vercruysse GA; Rozycki GS; Feliciano DV
    Am Surg; 2011 Aug; 77(8):1043-9. PubMed ID: 21944521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion.
    Spinella PC; Perkins JG; McLaughlin DF; Niles SE; Grathwohl KW; Beekley AC; Salinas J; Mehta S; Wade CE; Holcomb JB
    J Trauma; 2008 Feb; 64(2):286-93; discussion 293-4. PubMed ID: 18301188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion.
    Perkins JG; Schreiber MA; Wade CE; Holcomb JB
    J Trauma; 2007 May; 62(5):1095-9; discussion 1099-101. PubMed ID: 17495707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case-control study.
    H-Y CS; Xuemei C; G KR; M BL; V HG; A SF; K FS
    BMC Neurol; 2012 Dec; 12():158. PubMed ID: 23241423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of recombinant factor VIIa treatment for massive hemorrhage in patients with multiple traumas.
    Koh YR; Cho SJ; Yeom SR; Chang CL; Lee EY; Son HC; Kim HH
    Ann Lab Med; 2012 Mar; 32(2):145-52. PubMed ID: 22389882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Recombinant Factor VII as Rescue for Severe Perioperative Bleeding in HeartMate II Recipients.
    Karimi A; Daigle SS; Smith WB; Janelle GM; Klodell CT
    J Card Surg; 2015 Jun; 30(6):500-5. PubMed ID: 25939953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
    Simpson E; Lin Y; Stanworth S; Birchall J; Doree C; Hyde C
    Cochrane Database Syst Rev; 2012 Mar; (3):CD005011. PubMed ID: 22419303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of thromboembolism formation following the use of recombinant factor VIIa in patients suffering from blunt force trauma compared with penetrating trauma: a systematic review.
    Devlin R; Bonanno L; Badeaux J
    JBI Database System Rev Implement Rep; 2016 Mar; 14(3):116-38. PubMed ID: 27532142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events.
    Brophy GM; Candeloro CL; Robles JR; Brophy DF
    Ann Pharmacother; 2013 Apr; 47(4):447-54. PubMed ID: 23535812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recombinant factor VIIa for the treatment of exsanguinating trauma patients: a matched-pair analysis from the Trauma Registry of the German Society for Trauma Surgery].
    Wafaisade A; Lefering R; Maegele M; Helm P; Braun M; Paffrath T; Bouillon B;
    Unfallchirurg; 2013 Jun; 116(6):524-30. PubMed ID: 22699315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
    Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
    Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global differences in causes, management, and survival after severe trauma: the recombinant activated factor VII phase 3 trauma trial.
    Christensen MC; Parr M; Tortella BJ; Malmgren J; Morris S; Rice T; Holcomb JB;
    J Trauma; 2010 Aug; 69(2):344-52. PubMed ID: 20699743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with recombinant activated factor VII in a series of 45 trauma patients.
    Felfernig M;
    J R Army Med Corps; 2007 Mar; 153(1):32-9. PubMed ID: 17575875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.
    Hauser CJ; Boffard K; Dutton R; Bernard GR; Croce MA; Holcomb JB; Leppaniemi A; Parr M; Vincent JL; Tortella BJ; Dimsits J; Bouillon B;
    J Trauma; 2010 Sep; 69(3):489-500. PubMed ID: 20838118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
    Lin Y; Stanworth S; Birchall J; Doree C; Hyde C
    Cochrane Database Syst Rev; 2011 Feb; (2):CD005011. PubMed ID: 21328270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIIa as last-resort treatment of desperate haemorrhage.
    Palmason R; Vidarsson B; Sigvaldason K; Ingimarsson JP; Gudbjartsson T; Sigurdsson GH; Onundarson PT
    Acta Anaesthesiol Scand; 2012 May; 56(5):636-44. PubMed ID: 22489992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding.
    Payen JF; Berthet M; Genty C; Declety P; Garrigue-Huet D; Morel N; Bouzat P; Riou B; Bosson JL;
    Br J Anaesth; 2016 Oct; 117(4):470-476. PubMed ID: 28077534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.